A Canadian court has handed out a decision preventing Indian drug giant Ranbaxy Laboratories Ltd. from selling a generic version of Pfizer's cholesterol-lowering drug Lipitor. At issue is a crystalline form of atorvastatin, an active ingredient in Lipitor, to which Pfizer has exclusive rights until 2016.

Full Story:

Related Summaries